Skip to main content
OpenTrials
Completed

NCT Number: NCT01901510

Panchromoendoscopy Using Oral Indigo Carmine Mixed With Polyethylene Glycol Prep

This study first is designed to see what dose of indigo carmine ingested orally mixed with the standard colonoscopy prep is needed to provide adequate staining of the right colon. It then will use this adequate staining concentration of Indigo Carmine to study whether this dye will increase the detection of polyps during colonoscopy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States

About this study

Colon cancer occurs in 5% of the US population. Currently colon cancer screening is recommended at the age of 50 years old for all patients who are at average risk. Colonoscopy is considered the gold standard test for colon cancer screening. This is partly because colonoscopy not only can detect polyps which are cancer precursors but also can remove them, and thereby detecting cancer and its precursors and preventing cancer. Unfortunately recent data suggest that colonoscopy can miss a significant percentage of polyps, especially on the right side of the colon. It is thought that one of the major reasons for missing polyps in the right side of the colon is the fact that they are flat or sessile serrated adenoma, both of which are more difficult than protruding polyps to identify with ordinary colon preparation and colonoscopes. Chromoendoscopy is the application of dye during colonoscopy to enhance detection of polyps. It has been shown that it improves the detection of polyps and thus has the potential of improving the performance of colonoscopy and increasing the detection of these difficult to detect polyps. It is however cumbersome and time consuming, which has discouraged its use. Indigo carmine, one commonly used dye, is actually FDA approved as a food colorant and can be consumed orally. It is minimally absorbed. In addition it is used intravenously for diagnosis of injuries of the urinary system because it is very rapidly excreted by the kidneys. The investigators believe that taking it orally will be well tolerated, and that any of the dye that is absorbed will be rapidly excreted by the kidneys and thus quickly eliminated without any side effects. Effective staining of the colon with indigo carmine and increased detection of polyps could change the current standard of care for screening for colon cancer.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients presenting for screening or surveillance colonoscopy
  • Must be aged 50 to 75 yrs
  • Must be able and willing to sign informed consent

Exclusion criteria

  • Known Creatinine >1.2
  • Cirrhosis
  • Pregnancy or breast feeding
  • History of anaphylaxis to any dye
  • History of bowel surgery or small bowel obstruction
  • History of aspiration
  • History of dysphagia
  • American Society of Anesthesia class >2
  • History of abnormal liver function test in the last year
  • History of any degree of cytopenia in the last year

Treatment and study plan

Chromoendoscopy (Indigo Carmine)

Drug

Indigo Carmine will be added to the colonic prep to attempt indirect chromoendoscopy

Other names: Indirect chromoendoscopy, Colonoscopy

Control

Other

The control will have minimal Indigo Carmine added to the colonic prep. This will serve to color the solution blue for blinding but not enough to provide significant staining for chromoendoscopy.

Primary outcomes

  1. Dose of indigo carmine needed to provide adequate chromoendoscopy of the right sided colon

    Time frame: 24 hours

    The dose in Indigo Carmine in mg per 1/8 - 1/2 gallon needed to provide adequate staining of the cecum and ascending colon.

Secondary outcomes

  1. Cecal intubation rate

    Time frame: 24 hours

  2. Time to cecal intubation

    Time frame: 24 hours

  3. Withdrawal time

    Time frame: 24 hours

  4. Quality of bowel preparation

    Time frame: 24 hours

    The Boston Bowel Preparation Scale will be used to grade the quality of the colonic prep:

    0 = Unprepared colon segment with mucosa not seen due to solid stool that cannot be cleared.

    • = Portion of mucosa of the colon segment seen, but other areas of the colon segment not well seen due to staining, residual stool and/or opaque liquid.
    • = Minor amount of residual staining, small fragments of stool and/or opaque liquid, but mucosa of colon segment seen well.
    • = Entire mucosa of colon segment seen well with no residual staining, small fragments of stool or opaque liquid.
  5. Patient tolerance of indigo carmine solution

    Time frame: 30 days

    The rate side effects experienced in the active arm versus the control arm will be compared to determine if side effects experienced are different in both groups. Known common side effect from the Polyethylene based colonic preparation include:

    Malaise Abdominal distension Anal irritation Nausea Abdominal pain Vomiting Rigors Thirst

  6. Quality of staining of the entire colon

    Time frame: 24 hours

    Chromoendoscopy quality:

    Scoring for 3 areas of the colon will be recorded separately:

    Right sided, transverse, left sided Distribution of staining in each area: 0 none, covering less than 50% = 1, patchy covering more than 50%=2, staining most of the mucosa (>80%) =3

    Intensity of staining: none = 0, poor= 1, fair =visible but not obscuring the vasculature, good= visible and obscuring the vasculature.

  7. Adenoma detection rate

    Time frame: 2 weeks

  8. Total number of non rectal serrated polyps detected

    Time frame: 2 weeks

  9. Total number of sessile serrated adenoma detected

    Time frame: 2 weeks

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Jul 17, 2013
Registry last updated
Mar 3, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.